- Report
- March 2024
- 191 Pages
Global
From €3257EUR$3,374USD£2,794GBP
€3619EUR$3,749USD£3,104GBP
- Report
- April 2024
- 137 Pages
Global
From €3763EUR$3,899USD£3,228GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1448EUR$1,500USD£1,242GBP
- Clinical Trials
- April 2024
- 65 Pages
Global
From €1448EUR$1,500USD£1,242GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1206EUR$1,250USD£1,035GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1206EUR$1,250USD£1,035GBP
- Report
- August 2022
- 113 Pages
Global
From €4585EUR$4,750USD£3,933GBP
- Report
- January 2022
- 200 Pages
Global
From €7239EUR$7,500USD£6,210GBP
- Report
- January 2022
- 200 Pages
Global
From €7239EUR$7,500USD£6,210GBP
- Report
- January 2022
- 60 Pages
Global
From €3813EUR$3,950USD£3,270GBP
- Report
- January 2022
- 60 Pages
Global
From €3813EUR$3,950USD£3,270GBP
- Report
- January 2022
- 60 Pages
Global
From €3813EUR$3,950USD£3,270GBP
- Report
- August 2019
Global
From €4343EUR$4,500USD£3,726GBP
- Report
- September 2022
- 176 Pages
Global
From €2413EUR$2,500USD£2,070GBP
- Clinical Trials
- November 2021
- 323 Pages
Global
From €2413EUR$2,500USD£2,070GBP
- Clinical Trials
- December 2019
- 140 Pages
Global
From €2413EUR$2,500USD£2,070GBP
- Report
- June 2020
- 69 Pages
Asia Pacific
From €1448EUR$1,500USD£1,242GBP
- Report
- June 2020
- 155 Pages
Global
From €3475EUR$3,600USD£2,981GBP
- Report
- June 2020
- 69 Pages
Europe
From €1448EUR$1,500USD£1,242GBP
- Report
- June 2020
- 69 Pages
Middle East, Africa
From €1448EUR$1,500USD£1,242GBP
Neutropenia Drug is a type of drug used to treat immune disorders, specifically those that involve a decrease in the number of neutrophils, a type of white blood cell. Neutropenia can be caused by a variety of conditions, including chemotherapy, radiation therapy, and certain infections. Neutropenia drugs are designed to increase the number of neutrophils in the body, helping to reduce the risk of infection and other complications. These drugs are typically administered intravenously or orally, depending on the severity of the condition.
The Neutropenia Drug market is highly competitive, with a number of companies offering products to treat this condition. Some of the major players in this market include Amgen, Novartis, Pfizer, Merck, and Roche. These companies offer a range of products, including monoclonal antibodies, cytokines, and other biologics. Additionally, there are a number of smaller companies that offer generic versions of these drugs. Show Less Read more